Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchtirzepatideglp-1periodontitistype 2 diabetestrinetx

Tirzepatide linked to lower periodontitis risk than GLP-1 agonists in 196,000 patients

In the matched TriNetX cohort, tirzepatide users had a hazard ratio of 0.70 for periodontitis and 0.69 for one-year mortality.

PR
By Priya Raman · Science Reporter
Sep 19 20:00 ETSource: Diabetes research and clinical practice

The wire

  1. 01A retrospective TriNetX cohort matched 97,993 adults with type 2 diabetes on tirzepatide to the same number on GLP-1 receptor agonists, finding lower one-year risks of periodontitis, tooth extraction, peri-implant complications and oral infections.
  2. 02The composite oral and periodontal outcome favored tirzepatide with a hazard ratio of 0.87, a signal clinicians managing diabetic patients with dental disease may want to track.
  3. 03Event rates were low and the data came from electronic health records, so the authors call for prospective studies with systematic dental assessment.

From the source

Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study

Diabetes research and clinical practice · 2026 Sep 20 · Tu CY, Chen HL, Wu YH et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42764072/